Loading stock research

Cellbxhealth PLC

ANPCF

HealthcareOTCGB

Sign in to save

$0.0199

$0.00 (+0.00%)

Overview Financials Analysis Valuation Thesis Ownership Compare AI Report News

ANPCF News

News and disclosures filtered by period, publisher, and event group.

1 / 1

Filter options

Results

Select a headline to open the full news page in the app.

May 18, 2026, 2:39 AMproactiveinvestors.co.ukANPCF

CelLBxHealth strikes US clinical collaboration with AdventHealth cancer studies

Company announcements

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed circulating tumour cell (CTC) diagnostics company, has secured a collaboration with AdventHealth, one of the largest faith-based health systems in the United States, to deploy its Parsortix platform in two clinical cancer studies. The trials, titled ACTION and SUNRISE, will use CelLBxHealth's technology to isolate and analyse CTCs from blood samples taken from patients undergoing treatment for colon, gastrointestinal and lung cancers.

Loading disclosure news